Exiqon Reaffirms Plan to Pursue miRNA Dx Only Through Partnerships, Provides Few Details on Programs
February 25, 2010
Exiqon Reaffirms Plan to Pursue miRNA Dx Only Through Partnerships, Provides Few Details on Programs
The company also reported its financial results for 2009, posting a slight increase in its net loss for the year, which included the impact of operations from its now-discontinued Oncotech unit.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Exiqon to Shut Down California Lab After Reimbursement Issue Stymies Sale Talks
June 10, 2010 / Gene Silencing News - Exiqon Sees Partnership for miRNA Dx by End of 2010
August 26, 2010 / Gene Silencing News - Exiqon to Sell Calif. CLIA Lab to Gain 'Efficiencies,' Free Up Resources
December 17, 2009 / Gene Silencing News - Exiqon, Asuragen Ink Deal to Offer microRNA PCR-based Services
June 10, 2013 / GenomeWeb Daily News - Danish Partners Embark on $6.8M Personalized Cancer Diagnostics Project
June 5, 2013 / GenomeWeb Daily News